ACLS Update and Beta Blockers in Recalcitrant Ventricular Fibrillation

This month, Journal Club kicks off our 2017-2018 academic year and we would like to extend a warm welcome to our new interns, fellows and your significant others. This month JC will discuss the topic of ACLS resuscitation and the use of novel approaches to managing the cardiac arrest victim. In particular, we will be looking at the role of b-blockers in recalcitrant VF. Despite the collective experience of our group having hundreds of cardiac arrest victims come through our ED’s, I expect none of our partners feels that she or he is a true expert. Evidence for much of what we do is pretty weak and our outcomes are generally very poor so, not much of a framework for developing expertise. One of the biggest “fears” of internship is that first solo resuscitation and I believe our JC discussion will help provide context for our newbies and I expect some great advice. We welcome a BIG turnout from our community faculty who always provide their excellent “real world” perspectives. 

Innes G. Successful hospitalization of patients with no discernible pathology. CJEM. 2000 Jan;2(1):47-51.

Driver BE Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with refractory ventricular fibrillation. Resuscitation.2014 Oct85(10):1337-41.

 Miwa Y Effects of landiolol, an ultra-short-acting beta1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J. 2010 May;74(5):856-63. Epub 2010 Mar 26.

 Lee YH Refractory ventricular fibrillation treated with esmolol. Resuscitation. 2016 Oct;107:150-5.